Hadassah

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Wednesday, Dec 17 2014

A new drug technology, developed at the Hadassah Medical Organization to treat fatty liver disease--a condition with no approved effective drug treatment--was given the go-ahead by the United States Food and Drug Administration (FDA) for a Phase 2 multi-center clinical trial in the US.

In its severe form (called nonalcoholic steatohepatitis-NASH), fatty liver disease can lead to cirrhosis and liver cancer. Current estimates reveal that at least five percent of the Western world’s population suffers from the disease. The majority of these patients also have diabetes, high blood lipids, and obesity.

The new technology was developed by Prof. Yaron Ilan, Director, Department of Internal Medicine and former president of the Israel Liver Association, and his team in Hadassah’s Liver Unit. Based on feeding natural antibodies against intestinal bacteria associated with fatty liver disease, the treatment reduces inflammation by directly affecting the activity level of regulatory T cells in the liver and fat tissues. “The new drug is based on a novel discovery that bacteria in our gut are relevant for the induction of inflammation in our body, which is associated with liver disease, diabetes, and obesity” said Prof. Ilan. “The new therapy is safe and has no side effect, and we hope the results of the phase II trial will enable us to move forward with its development as a treatment for diabetes and fatty liver disease”.

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron.

The multi-center clinical trial will involve 120 patients in several leading medical centers in the US and Australia. The cohort will receive the treatment for six months, while monitored for the state of their liver disease, diabetes, and lipid profile.

Clinical trials were already conducted at Hadassah, which confirmed the safety and efficacy of the treatment.

Read about the 2009 discovery of treatment for fatty liver disease

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

Friday, Apr 28 2017

Surgeons Perform World’s First-Ever Dual Robotic Surgery
 at Jerusalem’s Hadassah Hospital

The world’s first-of-its-kind dual robotic surgery was performed on April 23 at Hadassah Hospital Ein Kerem in Jerusalem, announced National President Ellen Hershkin of Hadassah, the Women’s Zionist Organization of America, Inc. (HWZOA).

READ MORE ›
alt_text

Tuesday, Apr 25 2017

Hadassah Performs World First Two-Robot Repair of Complex Spinal Break

Suffering six broken vertebrae and leg fractures in two places, Mr. Schwartz was brought to the underground hybrid operating room in Hadassah Hospital Ein Kerem’s Sarah Wetsman Davidson Hospital Tower. “In the hybrid room are two robots,” explains Prof. Meir Liebergall, head of Hadassah’s Orthopedic Department. “The more innovative of the two is the Zeego...

READ MORE ›
alt_text

Monday, Apr 24 2017

Hadassah Surgeon Saves Hands of Border Guards

It was cold and dark outside the Lions Gate of the Old City at 4 am on March 13, the day on which Jerusalem citizens were celebrating Purim.

READ MORE ›
alt_text

Monday, Apr 24 2017

Hadassah’s New Home Away from Home for Parents with Ill Children

Hadassah Hospital Mount Scopus now houses Israel’s first Pediatric Palliative and Supportive Care Center, a home away from home for parents and their children with chronic or terminal diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More